THIS MONTH’S ISSUE

Read, save, and print articles from the current issue

ARTICLES

Chronological index
2013–2018

PRODUCT GUIDES

Compare all instruments
and software systems

DEPARTMENTS

Chronological index
2013–2018

WEBINARS

Register Now and
On Demand

Home » Top news

Myriad Genetics to acquire Counsyl

June 4, 2018Myriad Genetics has signed a definitive agreement to acquire Counsyl for $375 million in cash and stock. Counsyl, founded in 2007, has generated more than $134 million in revenue in the past 12 months and performed more than 280,000 reproductive genetic tests.

“By offering Counsyl’s best-in-class reproductive testing products in conjunction with Myriad’s leading hereditary cancer tests, we are well positioned to be the premier women’s health genetic testing company,” Mark C. Capone, president and CEO of Myriad Genetics, said in a press release. “The Counsyl management team has a remarkable track record of success, and combining our commercial capabilities will lead to a threefold increase in physician reach for Counsyl’s reproductive tests.”

Counsyl will become a wholly owned subsidiary of Myriad once the transaction has closed, which is expected in early 2019. Counsyl’s products include the Foresight test for carrier screening, the Prelude test for prenatal screening, and the Reliant test, which screens for hereditary cancers.

More top news

Print Friendly, PDF & Email
Tags: ,

X